June 28, 2022
Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236
June 9, 2022
Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference
May 9, 2022
Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress
April 21, 2022
Revolution Medicines to Report Financial Results for First Quarter 2022 After Market Close on May 9, 2022
March 9, 2022
Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022
March 1, 2022
Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference
February 28, 2022
Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress
February 22, 2022
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February 28, 2022
February 3, 2022
Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference
January 11, 2022
Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentation at 40th Annual J.P. Morgan Healthcare Conference